1. Home
  2. UAA vs INBX Comparison

UAA vs INBX Comparison

Compare UAA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UAA

Under Armour Inc.

N/A

Current Price

$4.67

Market Cap

1.9B

ML Signal

N/A

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

N/A

Current Price

$98.94

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UAA
INBX
Founded
1996
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.5B
IPO Year
2005
2024

Fundamental Metrics

Financial Performance
Metric
UAA
INBX
Price
$4.67
$98.94
Analyst Decision
Hold
Buy
Analyst Count
27
4
Target Price
$6.27
★ $266.67
AVG Volume (30 Days)
★ 8.0M
282.4K
Earning Date
11-05-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $4,966,370,000.00
$1,300,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.51
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 550.00
52 Week Low
$4.13
$28.16
52 Week High
$8.15
$155.29

Technical Indicators

Market Signals
Indicator
UAA
INBX
Relative Strength Index (RSI) 32.64 43.08
Support Level N/A $96.60
Resistance Level $5.39 $106.40
Average True Range (ATR) 0.18 5.75
MACD -0.01 -1.44
Stochastic Oscillator 24.60 11.13

Price Performance

Historical Comparison
UAA
INBX

About UAA Under Armour Inc.

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: